Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $19.00.

A number of brokerages recently weighed in on ARTV. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Thursday, October 30th. Wedbush lifted their target price on Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, October 17th. HC Wainwright increased their price target on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 17th.

Artiva Biotherapeutics Trading Up 3.6%

Shares of ARTV opened at $3.71 on Friday. The business’s 50 day moving average is $3.55 and its 200 day moving average is $2.78. Artiva Biotherapeutics has a 12-month low of $1.47 and a 12-month high of $13.19. The company has a market capitalization of $91.08 million, a PE ratio of -1.44 and a beta of 3.06.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. Equities research analysts predict that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Fred Aslan sold 25,500 shares of the business’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $6.00, for a total value of $153,000.00. Following the sale, the chief executive officer owned 356,721 shares in the company, valued at approximately $2,140,326. The trade was a 6.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 21.40% of the company’s stock.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ARTV. Citadel Advisors LLC raised its position in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets raised its position in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Artiva Biotherapeutics by 26.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock valued at $165,000 after purchasing an additional 11,355 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at approximately $79,000. Finally, Nuveen LLC purchased a new position in shares of Artiva Biotherapeutics in the 1st quarter worth approximately $144,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.